AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20564081
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy alone (Control group, n=38)
Trial: 8866042
Drug: Flurbiprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (200 mg multiple-unit sustained release capsule) after overnight fast
Trial: 8866042
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg erodible sustained release matrix tablet) after overnight fast
Trial: 1507928
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg magnesium‐DL‐hydrogen aspartate
Trial: 1507928
Drug: magnesium‐L‐hydrogen aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: magnesium‐L‐hydrogen aspartate
Trial: 6653132
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg flunitrazepam
Trial: 30396363
Drug: Medetomidine (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medetomidine (3.0 μg/kg/h)
Trial: 30396363
Drug: Medetomidine (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medetomidine (3.0 μg/kg/h) and Propofol (3.0 mg/kg/h)
Trial: 30396363
Drug: Medetomidine (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medetomidine (3.0 μg/kg/h) and Propofol (6.0 mg/kg/h)
Trial: 19874329
Drug: Levothyroxine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine plus 5 mg/day desloratadine (suppression group, n = 8)
Trial: 19874329
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day desloratadine alone (control group, n = 7)
Trial: 12011967
Drug: HR (Paroven,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) 1 g, twice daily for 6 months
Trial: 10930636
Drug: Tramadol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.5 mg kg(‐1)
Trial: 14649346
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg kg(‐1)
Trial: 8250358
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml per m2 of body surface area of carbonated 1% lignocaine, 0.25% bupivacaine or a 1 to 1 mixture of both.
Trial: 29682022
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate 40 mg injected into each level (Group 1)
Trial: 27769202
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT) - 10,000 Lux
Trial: 8843961
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (bleomycin, vincristine, mitolactol, methotrexate, 3 courses)
Trial: 28404197
Drug: Mercaptopurine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mercaptopurine (1 mg/kg bodyweight, rounded to nearest 25 mg)
Trial: 22874843
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium load
Trial: 6132613
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg kg‐1
Trial: 6132613
Drug: Diazemuls 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazemuls 0.15 mg kg‐1
Trial: 28945493
Drug: 1.23% acidulated
RxNorm normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% acidulated phosphate fluoride (APF) gel with cold atmospheric plasma (CAP)
Trial: 27120271
Drug: 61% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 61% ethanol solution with 1% chlorhexidine gluconate (ES/CH)
Trial: 27120271
Drug: 30% 1‐propanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% 1‐propanol and 45% 2‐propanol solution (MPS)
Trial: 27120271
Drug: 70% 2‐propanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% 2‐propanol solution (IPS)
Trial: 16925861
Drug: P supplement
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P supplement 250 mg
Trial: 16925861
Drug: P supplement
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P supplement 1500 mg
Trial: 10719952
Drug: Propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration in patients older than 60 years
Trial: 10719952
Drug: Bolus data
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus data for propofol administration
Trial: 9021354
Drug: Sequential step‐up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential step‐up and step‐down protocol
Trial: 18687168
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and Propofol combination
Trial: 3931136
Drug: lorazepam 2.5
RxNorm normalized name: lorazepam 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam 2.5 mg
Trial: 31813635
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam accelerated partial breast irradiation (APBI) - 38.5 Gy in ten fractions delivered twice per day over 5-8 days
Trial: 15337326
Drug: Olanzapine (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5‐20 mg) added to mood stabilizer therapy
Trial: 15337326
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to mood stabilizer therapy
Trial: 12230419
Drug: Extended thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended thromboprophylaxis with warfarin for 4 more weeks
Trial: 12230419
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (stopped warfarin at hospital discharge)
Trial: 9686768
Drug: Tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 mg three times a day for 8 weeks
Trial: 9686768
Drug: Tolcapone with
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone with oral selegiline (5 mg in the morning and midday) during the second 4 weeks
Trial: 11432215
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus cooling blanket (18 degrees C)
Trial: 9209244
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg/day during 6 days)
Trial: 2893564
Drug: Vecuronium 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.12 mg/kg
Trial: 22374331
Drug: oral sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral sorafenib 400 mg twice a day
Trial: 17669023
Drug: rhBMP‐2/ACS (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP‐2/ACS (0.2 mg/mL)
Trial: 17669023
Drug: rhBMP‐2/ACS (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP‐2/ACS (0.56 mg/mL)
Trial: 10657735
Drug: Estradiol treatment
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol treatment (0.1 mg 17beta-estradiol daily via transdermal patches)
Trial: 10657735
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (placebo via transdermal patches)
Trial: 10657735
Drug: Dexamethasone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1.5 mg) and hCRH (100 microgram)
Trial: 7596696
Drug: Unsuccessful biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsuccessful biofeedback treatment
Trial: 7352955
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g vitamin C daily (Group III)
Trial: 7352955
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g vitamin C daily for the first 20 days (in a separate group of 40 patients with acute myocardial infarction)
Trial: 26604721
Drug: GCQID group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCQID group (1,200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, 45 mg type II collagen peptides, 90 mg quercetin glycosides, 10 mg imidazole peptides, 5 μg vitamin D per day)
Trial: 23355041
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of gemcitabine and S‐1
Trial: 26308942
Drug: Gemcitabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine monotherapy
Trial: 21188597
Drug: Intranasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroid (INS) therapy (mometasone furoate)
Trial: 12728284
Drug: Etanercept (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (TNF antagonist)
Trial: 10417520
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin applied for 24 h
Trial: 8936891
Drug: School-based, nurse-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based, nurse-administered relaxation training
Trial: 1660823
Drug: Azithromycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1.5 g in five or six doses over 5 days)
Trial: 1660824
Drug: Erythromycin (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (14 or 20 g in 28 or 40 doses over 7 or 10 days)
Trial: 1660824
Drug: Amoxycillin (10.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (10.5 g in 21 doses over 7 days)
Trial: 7076116
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Trial: 7076116
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5 mg per kg per day of chenodeoxycholic acid (CDCA) and 5 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Trial: 7076116
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per kg per day of chenodeoxycholic acid (CDCA) for 45 to 60 days
Trial: 7076116
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per kg per day of chenodeoxycholic acid (CDCA)
Trial: 14587303
Drug: Val 160
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Val 160 mg
Trial: 14587303
Drug: Val 160
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Val 160 mg/HCTZ 12.5 mg
Trial: 14587303
Drug: Val 160
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Val 160 mg/HCTZ 25 mg
Trial: 10491452
Drug: Misoprostol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800 or 1600 microg daily)
Trial: 1790547
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg orally every 12 hours for 10 days
Trial: 29048966
Drug: Weekly SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly SMS message group
Trial: 29048966
Drug: Weekly SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly SMS message with response option group
Trial: 25109720
Drug: Gamma oryzanol
RxNorm normalized name: GAMMA ORYZANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma oryzanol supplementation (600 mg/day)
Trial: 23045591
Drug: Tamoxifen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen and exemestane treatment
Trial: 16055868
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Tiotropium + Formoterol) q.d.
Trial: 9545143
Drug: Statins (HMG-coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (HMG-coenzyme A reductase inhibitors)
Trial: 8006330
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g oral ARG (group D)
Trial: 8006330
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g i.v. ARG (group C)
Trial: 20516313
Drug: Active motion
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active motion therapy (place-and-hold)
Trial: 20516313
Drug: Passive motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive motion therapy
Trial: 8831305
Drug: Aprotinin treatment
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin treatment
Trial: 10437237
Drug: Fufang Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Danshen Tablet
Trial: 3534568
Drug: 14-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-valent pneumococcal capsular polysaccharide vaccine
Trial: 2681554
Drug: Ifosfamide plus
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide plus doxorubicin (doxorubicin 60 mg/m2 by continuous push, ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna 7.5 g/m2 over 36 hours, courses every 3 weeks)
Trial: 30572837
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg tramadol
Trial: 30819084
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment with clozapine
Trial: 16603829
Drug: Lipid-lowering agents
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering agents
Trial: 18295467
Drug: Zinc picolinate
RxNorm normalized name: Zinc picolinate
DrugBank: Zinc picolinate (DB11175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc picolinate supplementation (22 mg daily for 8 weeks)
Trial: 8807761
Drug: Intensive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antibiotic therapy plus early ultrasound-guided vaginal drainage
Trial: 8807761
Drug: Intensive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antibiotic therapy alone
Trial: 23797954
Drug: Oral ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ascorbic acid (AA) 4 g/d
Trial: 14581270
Drug: Letrozole as
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole as first-line therapy
Trial: 14581270
Drug: Tamoxifen as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen as first-line therapy
Trial: 20380750
Drug: Traumeel tablets
RxNorm normalized name: TRAUMEEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traumeel tablets
Trial: 16131466
Drug: Subcutaneous block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous block
Trial: 12704016
Drug: Comprehensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive intervention plus 2 monthly booster sessions
Trial: 1101933
Drug: Total body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total body radiation therapy
Trial: 25912697
Drug: Serelaxin 30
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin 30 µg·kg(‐1)·day(‐1)
Trial: 19170716
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg) for 16 weeks
Trial: 15289797
Drug: Rivastigmine 6-12
RxNorm normalized name: rivastigmine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 6-12 mg/day
Trial: 10979055
Drug: Diuretics, beta-blockers,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium antagonists
Trial: 1397666
Drug: Nicardipine hydrochloride/HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride/HCTZ (30 mg nicardipine three times daily)
Trial: 3925630
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of vinblastine, thiotepa, and 5-fluorouracil once a week
Trial: 3925630
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of vinblastine on days 1 and 2, thiotepa on day 3, and 5-fluorouracil on day 5, weekly
Trial: 23844826
Drug: Protective creams
RxNorm normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective creams (PCs) applied at a low dose (2 mg/cm²)
Trial: 23844826
Drug: Protective creams
RxNorm normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective creams (PCs) applied at a high dose (20 mg/cm²)
Trial: 18047870
Drug: Social communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social communication skills training (12 weekly group sessions, 1.5 hours each)
Trial: 12177793
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(‐1) x wk(‐1)
Trial: 12177793
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa at an initial dose of 150 U x kg(‐1) three times weekly
Trial: 12177793
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa at an initial dose of 40,000 U x wk(‐1)
Trial: 10023731
Drug: Navy's usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navy's usual treatment (exercise alone)
Trial: 7589031
Drug: Zileuton 200
RxNorm normalized name: zileuton 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 200 mg
Trial: 7589031
Drug: Zileuton 400
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton 400 mg
Trial: 29738286
Drug: Self-limiting excavation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-limiting excavation protocol using chemomechanical Carisolv gel/operating microscope
Trial: 25117817
Drug: Concurrent trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent trastuzumab (Arm C)
Trial: 25117817
Drug: Sequential trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential trastuzumab after chemotherapy (Arm B)
Trial: 9708936
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Arm A)
Trial: 22300946
Drug: HIV treatment-naive
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV treatment-naive patients
Trial: 22300946
Drug: Overall gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall gene expression across all treatment groups
Trial: 16142594
Drug: Fluvastatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin, 80 mg, p.o.
Trial: 23549582
Drug: V710 vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V710 vaccine, 60 μg (n = 4015)
Trial: 19494217
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg subcutaneously every 8 weeks
Trial: 15121733
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 5000 U/day plus low-dose aspirin
Trial: 15121733
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment intervention)
Trial: 30197142
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with 5 mL + 120 mL of sterile PBS (control; n = 12)
Trial: 12358250
Drug: Bran (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bran (15 g b.i.d.)
Trial: 30680828
Drug: Bimonthly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimonthly administration of Cetuximab at 500 mg/m2
Trial: 30680828
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of Cetuximab at 250 mg/m2
Trial: 27645341
Drug: Daclizumab 150mg
RxNorm normalized name: DACLIZUMAB 150MG/ML SYR
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab 150mg or 300mg monthly